BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15055861)

  • 1. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma.
    Hazar B; Polat G; Seyrek E; Bağdatoğlğlu O; Kanik A; Tiftik N
    Int J Clin Pract; 2004 Feb; 58(2):139-43. PubMed ID: 15055861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
    Urquhart A; Berg R
    Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients.
    Silva BO; Medeiros JW; Albuquerque GS; Valderrama PM; Barbosa AHQ; de Souza JM; Oliveira RS; Morais AL; Neto JDCS; Muniz MTC
    J Pediatr (Rio J); 2023; 99(1):59-64. PubMed ID: 35868407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
    Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
    Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of CD147 and matrix metalloproteinase-9 in children with non-Hodgkin's lymphoma and its correlation with prognosis].
    Liu AG; Hu Q; Tao HF; Liu SY; Zhang LQ; Hu Y
    Zhonghua Er Ke Za Zhi; 2009 Oct; 47(10):785-8. PubMed ID: 20021816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: a clinico-pathological and immuno-histochemical population-based study of 32 patients.
    Amini RM; Enblad G; Sundström C; Glimelius B
    Int J Cancer; 1997 May; 71(4):510-6. PubMed ID: 9178801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
    Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
    J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness.
    Aryee DN; Simonitsch I; Mosberger I; Kos K; Mann G; Schlögl E; Pötschger U; Gadner H; Radaszkiewicz T; Kovar H
    Br J Cancer; 1996 Dec; 74(11):1693-8. PubMed ID: 8956779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I; Pearce R; Taghipour G; Goldstone AH
    J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans.
    Kossakowska AE; Huchcroft SA; Urbanski SJ; Edwards DR
    Br J Cancer; 1996 Jun; 73(11):1401-8. PubMed ID: 8645587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma.
    Gonzalez CL; Medeiros LJ; Jaffe ES
    Am J Clin Pathol; 1991 Jul; 96(1):81-9. PubMed ID: 2069139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases and their tissue inhibitors - expression, role and regulation in human malignant non-Hodgkin's lymphomas.
    Kossakowska AE; Urbanski SJ; Janowska-Wieczorek A
    Leuk Lymphoma; 2000 Nov; 39(5-6):485-93. PubMed ID: 11342332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency.
    Kanavaros P; Jiwa M; van der Valk P; Walboomers J; Horstman A; Meijer CJ
    Hum Pathol; 1993 Jul; 24(7):725-9. PubMed ID: 8100553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree.
    Alexandrescu DT; Garino A; Brown-Balem KA; Wiernik PH
    Leuk Lymphoma; 2006 Oct; 47(10):2115-27. PubMed ID: 17071485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the matrix metalloproteinase 9 in Hodgkin's disease is independent of EBV status.
    Flavell JR; Baumforth KR; Williams DM; Lukesova M; Madarova J; Noskova V; Prochazkova J; Lowe D; Kolar Z; Murray PG; Nelson PN
    Mol Pathol; 2000 Jun; 53(3):145-9. PubMed ID: 10897334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease.
    Kingma DW; Medeiros LJ; Barletta J; Raffeld M; Mann RB; Ambinder RF; Jaffe ES
    Am J Surg Pathol; 1994 Jan; 18(1):48-61. PubMed ID: 8279628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas.
    Jaffe ES; Zarate-Osorno A; Kingma DW; Raffeld M; Medeiros LJ
    Ann Oncol; 1994; 5 Suppl 1():7-11. PubMed ID: 8172822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.